CY1117584T1 - Παραγωγα 1-βενζυλ-3-υδροξυμεθυλινδαζολης και η χρηση τους στη θεραπευτικη αντιμετωπιση νοσων που βασιζονται στην εκφραση των mcp-1, cx3cr1 - Google Patents
Παραγωγα 1-βενζυλ-3-υδροξυμεθυλινδαζολης και η χρηση τους στη θεραπευτικη αντιμετωπιση νοσων που βασιζονται στην εκφραση των mcp-1, cx3cr1Info
- Publication number
- CY1117584T1 CY1117584T1 CY20161100406T CY161100406T CY1117584T1 CY 1117584 T1 CY1117584 T1 CY 1117584T1 CY 20161100406 T CY20161100406 T CY 20161100406T CY 161100406 T CY161100406 T CY 161100406T CY 1117584 T1 CY1117584 T1 CY 1117584T1
- Authority
- CY
- Cyprus
- Prior art keywords
- mcp
- benzyl
- hydroxymethyldazole
- expressing
- derivative
- Prior art date
Links
- 102100021943 C-C motif chemokine 2 Human genes 0.000 title abstract 3
- 101710155857 C-C motif chemokine 2 Proteins 0.000 title abstract 3
- 230000001225 therapeutic effect Effects 0.000 title 1
- AKQDXNFPEFHRLS-UHFFFAOYSA-N (1-benzylindazol-3-yl)methanol Chemical class C12=CC=CC=C2C(CO)=NN1CC1=CC=CC=C1 AKQDXNFPEFHRLS-UHFFFAOYSA-N 0.000 abstract 2
- 108090000835 CX3C Chemokine Receptor 1 Proteins 0.000 abstract 2
- 102100039196 CX3C chemokine receptor 1 Human genes 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 1
- 230000006806 disease prevention Effects 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003937 drug carrier Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
- C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/04—Drugs for disorders of the respiratory system for throat disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Pulmonology (AREA)
- Biomedical Technology (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Virology (AREA)
- Dermatology (AREA)
- Endocrinology (AREA)
- Communicable Diseases (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Rheumatology (AREA)
- Transplantation (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Child & Adolescent Psychology (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Molecular Biology (AREA)
- Pain & Pain Management (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP08425139 | 2008-03-07 | ||
| EP09718467.5A EP2254870B1 (en) | 2008-03-07 | 2009-03-05 | 1-benzyl-3-hydroxymethylindazole derivatives and use thereof in the treatment of diseases based on the expression of mcp-1, cx3cr1 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1117584T1 true CY1117584T1 (el) | 2017-04-26 |
Family
ID=39671487
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20161100406T CY1117584T1 (el) | 2008-03-07 | 2016-05-13 | Παραγωγα 1-βενζυλ-3-υδροξυμεθυλινδαζολης και η χρηση τους στη θεραπευτικη αντιμετωπιση νοσων που βασιζονται στην εκφραση των mcp-1, cx3cr1 |
| CY20171100858T CY1119252T1 (el) | 2008-03-07 | 2017-08-09 | Νεα παραγωγα 1-βενζυλο-3 -υδροξυμεθυλινδαζολης και χρηση αυτων στη θεραπεια νοσων που βασιζονται στην εκφραση των cx3cr1 και ρ40 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20171100858T CY1119252T1 (el) | 2008-03-07 | 2017-08-09 | Νεα παραγωγα 1-βενζυλο-3 -υδροξυμεθυλινδαζολης και χρηση αυτων στη θεραπεια νοσων που βασιζονται στην εκφραση των cx3cr1 και ρ40 |
Country Status (25)
| Country | Link |
|---|---|
| US (3) | US7919518B2 (OSRAM) |
| EP (3) | EP3181551A1 (OSRAM) |
| JP (2) | JP5509101B2 (OSRAM) |
| KR (2) | KR101581828B1 (OSRAM) |
| CN (2) | CN101952256B (OSRAM) |
| AR (2) | AR070810A1 (OSRAM) |
| AU (2) | AU2009221089B2 (OSRAM) |
| BR (2) | BRPI0907976A2 (OSRAM) |
| CA (2) | CA2712703C (OSRAM) |
| CY (2) | CY1117584T1 (OSRAM) |
| DK (2) | DK2254869T3 (OSRAM) |
| EA (2) | EA018241B1 (OSRAM) |
| ES (2) | ES2637009T3 (OSRAM) |
| GE (2) | GEP20135912B (OSRAM) |
| HR (2) | HRP20171208T1 (OSRAM) |
| HU (1) | HUE027098T2 (OSRAM) |
| IL (3) | IL206893A0 (OSRAM) |
| LT (1) | LT2254869T (OSRAM) |
| MX (2) | MX2010009623A (OSRAM) |
| PL (2) | PL2254869T3 (OSRAM) |
| PT (1) | PT2254869T (OSRAM) |
| SG (1) | SG188177A1 (OSRAM) |
| SI (2) | SI2254869T1 (OSRAM) |
| UA (2) | UA103605C2 (OSRAM) |
| WO (2) | WO2009109618A2 (OSRAM) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5509102B2 (ja) | 2008-03-07 | 2014-06-04 | アジェンデ・キミケ・リウニテ・アンジェリニ・フランチェスコ・ア・チ・エレ・ア・エフェ・ソシエタ・ペル・アチオニ | 新規な１−ベンジル−３−ヒドロキシメチルインダゾール誘導体およびそのｍｃｐ−１およびｃｘ３ｃｒ１の発現に基づく疾患の治療への使用 |
| LT2254869T (lt) * | 2008-03-07 | 2017-08-10 | Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.P.A. | Nauji 1-benzil-3-hidroksimetilindazolo dariniai ir jų panaudojimas gydyme ligų, susijusių su cx3cr1 ir p40 raiška |
| CA2714436C (en) * | 2008-03-07 | 2017-06-27 | Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.P.A. | Novel 1-benzyl-3-hydroxymethylindazole derivatives and use thereof in the treatment of diseases based on the expression of mcp-1, cx3cr1 and p40 |
| PL2462119T3 (pl) * | 2009-08-03 | 2014-10-31 | Acraf | Sposób wytwarzania 1-benzylo-3-hydroksymetylo-1H-indazolu i jego pochodnych oraz potrzebnych magnezowych związków pośrednich |
| UA108742C2 (uk) * | 2009-09-23 | 2015-06-10 | Фармацевтична композиція для лікування запальних захворювань, опосередкованих mcp-1 | |
| CN104334173B (zh) * | 2012-05-01 | 2017-05-03 | 特兰斯拉图姆医学公司 | 用于治疗和诊断致盲性眼病的方法 |
| US8999292B2 (en) | 2012-05-01 | 2015-04-07 | Translatum Medicus Inc. | Methods for treating and diagnosing blinding eye diseases |
| MX347615B (es) | 2012-05-18 | 2017-05-04 | Sanofi Sa | Derivados de pirazol y su uso como antagonistas de lpar5. |
| US9346757B2 (en) | 2012-05-18 | 2016-05-24 | Sanofi | Pyridine derivatives and their use in the treatment of conditions associated with pathological thrombus formation |
| MX372807B (es) | 2012-11-09 | 2020-07-03 | Colgate Palmolive Co | Copolimeros de bloque para proteccion del esmalte dental. |
| EP3142664B1 (en) * | 2014-05-15 | 2019-12-04 | Translatum Medicus Inc. | Compositions and methods for treating and diagnosing ocular disorders |
| WO2016201426A1 (en) * | 2015-06-12 | 2016-12-15 | Vettore, LLC | Mct4 inhibitors for treating disease |
| WO2016203313A1 (en) * | 2015-06-16 | 2016-12-22 | Translatum Medicus, Inc. | Compositions and methods for treating and diagnosing ocular disorders |
| IL279949B2 (en) | 2016-12-12 | 2025-03-01 | Vettore Llc | Heterocyclic MCT4 inhibitors |
| GB201811169D0 (en) | 2018-07-06 | 2018-08-29 | Kancera Ab | New compounds |
| WO2020026471A1 (ja) * | 2018-07-31 | 2020-02-06 | 株式会社親広産業 | グルコース消費促進剤および解糖系促進剤 |
| JP6612004B1 (ja) * | 2018-07-31 | 2019-11-27 | 株式会社親広産業 | グルコース消費促進剤および解糖系促進剤 |
| US11753382B2 (en) | 2019-06-25 | 2023-09-12 | Translatum Medicus Inc. | Processes of making 2-((1-benzyl-1H-indazol-3-yl)methoxy)-2-methylpropanoic acid and its derivatives |
| CN113929627A (zh) * | 2021-10-19 | 2022-01-14 | 吕梁学院 | 一种宾达利的合成方法 |
| WO2024108386A1 (zh) * | 2022-11-22 | 2024-05-30 | 中国科学院深圳先进技术研究院 | 抗mcp1中和抗体在制备治疗神经退行性疾病引起的系统性炎症药物中的应用 |
| WO2024165925A1 (en) * | 2023-02-10 | 2024-08-15 | Translatum Medicus Inc. | Bindarit conjugates, compositions and methods for treating ocular diseases or disorders |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US416359A (en) * | 1889-12-03 | Sash-fastener | ||
| US364371A (en) * | 1887-06-07 | peice | ||
| IT1230441B (it) * | 1989-02-07 | 1991-10-23 | Acraf | Eteri della serie dell'indazolo |
| IT1253703B (it) * | 1991-04-22 | 1995-08-23 | Angelini Francesco Ist Ricerca | Uso di acidi metossi alcanoici dell'indazolo per preparare un farmaco attivo nel trattamento di malattie autoimmunitarie |
| IT1293795B1 (it) | 1997-07-28 | 1999-03-10 | Angelini Ricerche Spa | Farmaco attivo nel ridurre la produzione di proteina mcp-1 |
| WO2000078757A1 (en) | 1999-06-17 | 2000-12-28 | Shionogi Bioresearch Corp. | Inhibitors of il-12 production |
| EP1199074A1 (en) | 2000-09-15 | 2002-04-24 | Warner-Lambert Company | Pharmaceutical composition for preventing or treating a disease associated with an excess of il-12 production |
| EP1188438A1 (en) | 2000-09-15 | 2002-03-20 | Warner-Lambert Company | Pharmaceutical composition for preventing or treating a disease associated with an excess of Il-12 production |
| CA2440744C (en) | 2001-03-15 | 2009-12-08 | Seikagaku Corporation | Il-12 expression controlling agent |
| CN100349876C (zh) | 2001-11-30 | 2007-11-21 | 辛塔医药品有限公司 | 嘧啶化合物 |
| JP2007507494A (ja) | 2003-10-07 | 2007-03-29 | アストラゼネカ・アクチエボラーグ | ケモカイン受容体アンタゴニストとりわけＣＸ３ＣＲ１として有用な新規な２−置換４−アミノ−チアゾロ［４，５−ｄ］ピリミジン |
| ES2641815T3 (es) * | 2004-10-29 | 2017-11-14 | Eisai R&D Management Co., Ltd. | Tratamiento para enfermedades inflamatorias |
| JP2008519850A (ja) | 2004-11-10 | 2008-06-12 | シンタ ファーマシューティカルズ コーポレーション | Ｉｌ−１２調節化合物 |
| EP1827447A1 (en) | 2004-11-19 | 2007-09-05 | Synta Pharmaceuticals Corporation | Pyrimidine compounds and uses thereof |
| AR053347A1 (es) | 2005-04-06 | 2007-05-02 | Astrazeneca Ab | Derivados de [1,3]tiazolo[4,5-d]pirimidin-2(3h)-ona 5,7-sustituidos |
| UA90707C2 (en) | 2005-04-06 | 2010-05-25 | Астразенека Аб | Novel 5-substituted 7-amino-[1,3]thiazolo[4,5-d]pyrimidine derivatives |
| JP5509102B2 (ja) * | 2008-03-07 | 2014-06-04 | アジェンデ・キミケ・リウニテ・アンジェリニ・フランチェスコ・ア・チ・エレ・ア・エフェ・ソシエタ・ペル・アチオニ | 新規な１−ベンジル−３−ヒドロキシメチルインダゾール誘導体およびそのｍｃｐ−１およびｃｘ３ｃｒ１の発現に基づく疾患の治療への使用 |
| CA2714436C (en) * | 2008-03-07 | 2017-06-27 | Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.P.A. | Novel 1-benzyl-3-hydroxymethylindazole derivatives and use thereof in the treatment of diseases based on the expression of mcp-1, cx3cr1 and p40 |
| LT2254869T (lt) * | 2008-03-07 | 2017-08-10 | Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.P.A. | Nauji 1-benzil-3-hidroksimetilindazolo dariniai ir jų panaudojimas gydyme ligų, susijusių su cx3cr1 ir p40 raiška |
-
2009
- 2009-03-05 LT LTEP09717638.2T patent/LT2254869T/lt unknown
- 2009-03-05 KR KR1020107017806A patent/KR101581828B1/ko not_active Expired - Fee Related
- 2009-03-05 MX MX2010009623A patent/MX2010009623A/es active IP Right Grant
- 2009-03-05 CA CA2712703A patent/CA2712703C/en not_active Expired - Fee Related
- 2009-03-05 CA CA2712403A patent/CA2712403C/en not_active Expired - Fee Related
- 2009-03-05 AU AU2009221089A patent/AU2009221089B2/en not_active Ceased
- 2009-03-05 GE GEAP200911965A patent/GEP20135912B/en unknown
- 2009-03-05 BR BRPI0907976-9A patent/BRPI0907976A2/pt not_active IP Right Cessation
- 2009-03-05 GE GEAP200911963A patent/GEP20135983B/en unknown
- 2009-03-05 PL PL09717638T patent/PL2254869T3/pl unknown
- 2009-03-05 WO PCT/EP2009/052590 patent/WO2009109618A2/en not_active Ceased
- 2009-03-05 ES ES09717638.2T patent/ES2637009T3/es active Active
- 2009-03-05 BR BRPI0907977-7A patent/BRPI0907977A2/pt not_active IP Right Cessation
- 2009-03-05 WO PCT/EP2009/052585 patent/WO2009109613A2/en not_active Ceased
- 2009-03-05 EA EA201071038A patent/EA018241B1/ru not_active IP Right Cessation
- 2009-03-05 US US12/864,767 patent/US7919518B2/en not_active Expired - Fee Related
- 2009-03-05 EP EP17153930.7A patent/EP3181551A1/en not_active Withdrawn
- 2009-03-05 AU AU2009221083A patent/AU2009221083B2/en not_active Ceased
- 2009-03-05 PL PL09718467T patent/PL2254870T3/pl unknown
- 2009-03-05 EP EP09717638.2A patent/EP2254869B1/en active Active
- 2009-03-05 ES ES09718467.5T patent/ES2569330T3/es active Active
- 2009-03-05 MX MX2010009626A patent/MX2010009626A/es active IP Right Grant
- 2009-03-05 DK DK09717638.2T patent/DK2254869T3/en active
- 2009-03-05 JP JP2010549146A patent/JP5509101B2/ja active Active
- 2009-03-05 EA EA201071040A patent/EA019711B1/ru not_active IP Right Cessation
- 2009-03-05 HR HRP20171208TT patent/HRP20171208T1/hr unknown
- 2009-03-05 US US12/865,923 patent/US8835481B2/en not_active Expired - Fee Related
- 2009-03-05 SI SI200931705T patent/SI2254869T1/sl unknown
- 2009-03-05 CN CN200980105556.4A patent/CN101952256B/zh not_active Expired - Fee Related
- 2009-03-05 PT PT97176382T patent/PT2254869T/pt unknown
- 2009-03-05 HU HUE09718467A patent/HUE027098T2/en unknown
- 2009-03-05 CN CN200980105073.4A patent/CN101945855B/zh not_active Expired - Fee Related
- 2009-03-05 HR HRP20160462TT patent/HRP20160462T1/hr unknown
- 2009-03-05 DK DK09718467.5T patent/DK2254870T3/en active
- 2009-03-05 SG SG2013013123A patent/SG188177A1/en unknown
- 2009-03-05 KR KR1020107017445A patent/KR101599867B1/ko not_active Expired - Fee Related
- 2009-03-05 EP EP09718467.5A patent/EP2254870B1/en active Active
- 2009-03-05 SI SI200931404A patent/SI2254870T1/sl unknown
- 2009-03-05 JP JP2010549143A patent/JP5509099B2/ja active Active
- 2009-03-06 AR ARP090100800A patent/AR070810A1/es unknown
- 2009-03-06 AR ARP090100801A patent/AR070811A1/es unknown
- 2009-05-03 UA UAA201008883A patent/UA103605C2/uk unknown
- 2009-05-03 UA UAA201008570A patent/UA105170C2/uk unknown
-
2010
- 2010-07-08 IL IL206893A patent/IL206893A0/en not_active IP Right Cessation
- 2010-07-21 IL IL207131A patent/IL207131A/en not_active IP Right Cessation
-
2011
- 2011-03-07 US US13/041,557 patent/US8283348B2/en not_active Expired - Fee Related
- 2011-10-06 IL IL215579A patent/IL215579A/en not_active IP Right Cessation
-
2016
- 2016-05-13 CY CY20161100406T patent/CY1117584T1/el unknown
-
2017
- 2017-08-09 CY CY20171100858T patent/CY1119252T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1117584T1 (el) | Παραγωγα 1-βενζυλ-3-υδροξυμεθυλινδαζολης και η χρηση τους στη θεραπευτικη αντιμετωπιση νοσων που βασιζονται στην εκφραση των mcp-1, cx3cr1 | |
| CY1117504T1 (el) | Παραγωγα 1-βενζυλ-3-υδροξυμεθυλινδαζολης και η χρηση τους στη θεραπευτικη αντιμετωπιση νοσων που βασιζονται στην εκφραση των mcp-1, και cx3cr1 | |
| CY1122349T1 (el) | Παραγωγα 1-benzyλ-3-υδροξυμεθυλινδαζολης και χρηση αυτων στη θεραπεια νοσων που βασιζονται στην εκφραση των mcp-1, cxcr1 και ρ40 | |
| CY1124446T1 (el) | Μορφες δοσολογιας της ρουξολιτινιμπης παρατεταμενης αποδεσμευσης | |
| CY1121858T1 (el) | Παραγωγα αρυλμεθοξυ ισοϊνδολινης και συνθεσεις που περιλαμβανουν αυτες και μεθοδοι χρησης αυτων | |
| CY1122730T1 (el) | 1,2,4-τριαζολες ως διαμορφωτες πυρηνικης μεταφορας και χρησεις αυτων | |
| CY1121125T1 (el) | Συνθεσεις για τη θεραπευτικη αντιμετωπιση του πονου και/ή της φλεγμονης | |
| CY1119056T1 (el) | Παραγωγα 2',4',-διφθορο-2'-μεθυλ υποκατεστημενου νουκλεοσιδιου ως αναστολεις αντιγραφης hcv rna | |
| CY1126109T1 (el) | Αναστολεις toy trpc6 | |
| CY1119490T1 (el) | Παραγωγα πυραζολοπυρρολιδινης και η χρηση τους στην θεραπεια νοσηματων | |
| CY1120318T1 (el) | Υποκατεστημενες βενζυλινδαζολες για χρηση ως αναστολεις κινασης bub1 στη θεραπευτικη αντιμετωπιση υπερπολλαπλασιαστικων ασθενειων | |
| CY1120429T1 (el) | Παραγωγα κιναζολινης για τη θεραπευτικη αντιμετωπιση ιογενων λοιμωξεων και αλλων νοσων | |
| CY1115836T1 (el) | Παραγωγα πυραζινονης και η χρηση τους στη θεραπευτικη αντιμετωπιση παθησεων των πνευμονων | |
| CY1115289T1 (el) | Μεθοδοι αγωγης εναντι ασθενειας που σχετιζεται με φλεγμονη | |
| CY1119387T1 (el) | Τριαζολοπυραζινες ως αναστολεις brd4 για χρηση στην αντιμετωπιση καρκινου | |
| CY1117776T1 (el) | Εναντιομερη ενωσεων σπειρο-οξινδολιου και οι χρησεις τους ως θεραπευτικοι παραγοντες | |
| CY1112232T1 (el) | Κινολινικα παραγωγα ως αναστολεις φωσφοδιεστερασης | |
| CY1119487T1 (el) | Αναστολεις κιναζολινης των ενεργοποιητικων μεταλλαγμενων μορφων του υποδοχεα του επιδερμικου αυξητικου παραγοντα | |
| CY1118947T1 (el) | Ασυμμετρες ουριες και ιατρικες χρησεις αυτων | |
| CY1117719T1 (el) | Παραγωγα αμινοπυριμιδινης ως διαμορφωτες της lrrk2 | |
| CY1118340T1 (el) | Αναστολεις κινασης | |
| CY1118819T1 (el) | Ετεροκυκλικες ενωσεις αγωνιστες του υποδοχεα ip | |
| CY1114140T1 (el) | Ενωσεις 4-πυριδινονης και η χρηση αυτων για τον καρκινο | |
| CY1115262T1 (el) | Ανταγωνιστες trpv1 και χρησεις αυτων | |
| ATE557015T1 (de) | 3,4-diarylpyrazole als proteinkinaseinhibitoren |